How Philip Morris International Remade Itself Around the Product Killing Its Legacy Business

Philip Morris International built its fortune on cigarettes, but the product that defined its empire was also the one structurally guaranteed to shrink. Smoking rates in the US and across developed markets have been declining steadily. Philip Morris InternationalPM

, which sells Marlboro cigarettes outside the US, faced a compounding problem: its most profitable product was losing customers faster than organic innovation could replace them.

The decisive move came in 2022, when PMI closed a $16B acquisition of Swedish Match, the maker of Zyn nicotine pouches. That deal gave PMI something that would have taken years to build from scratch: a market-leading brand in the fastest-growing segment of the oral nicotine category. In 2022, Zyn shipped 238M cans in the US. PMI forecast that figure more than doubled by 2024.

What followed was a transformation Wall Street is still catching up to. Smoke-free products now account for 43% of total net revenue, up from a much smaller base just a few years ago. The company's stated target is to push that above two-thirds by 2030. Whether PMI can actually close that gap is the question the investment thesis turns on.

The Nicotine Gold Rush

PMI's revenue is now split between two engines pulling in opposite directions. In Q1 2026, organic smoke-free sales rose 5.3% while cigarettes managed 0.9% growth, per Bloomberg. Adjusted diluted earnings per share came in at $1.96 for the quarter, ahead of analyst estimates.

The Zyn business specifically grew 36% in 2025, a pace that reflects both category expansion and brand dominance. Nicotine pouches went from 4% of the oral tobacco and nicotine market in 2019 to 44% five years later, according to a 2025 study published in JAMA Network Open. PMI is scaling production to meet that demand head-on. The company committed $600M to build a new manufacturing facility in Aurora, Colorado, and an additional $232M to expand its plant in Owensboro, Kentucky.

Bonnie Herzog, a senior analyst at Goldman Sachs, laid out the financial logic plainly: "Their goal is by 2030, two-thirds of their revenue should be smoke-free. And ultimately they'd love it to be 100%. The beauty of this transformation is that they're actually generating faster top line and faster profitability given the pivot to these businesses."

Brand, Clearance, and a Culture That Can't Be Bought

PMI's competitive position around Zyn rests on three overlapping advantages: FDA regulatory clearance, production scale, and cultural penetration. Authorization from the FDA isn't just a legal permit to sell. It's a credibility signal that took years of scientific review to earn. The FDA recently released a policy allowing more pouch products onto retail shelves even before full authorization, provided companies have filed complete applications. That framework advantages incumbents with established filings over smaller new entrants trying to break in.

Production scale matters acutely in a physical goods category growing this fast. The combined $832M manufacturing commitment across two US facilities means supply constraints are less likely to cap Zyn's growth than they would for a smaller competitor scrambling to keep shelves stocked. Shelf presence and brand loyalty reinforce each other in convenience retail. A competitor who can't meet demand loses both.

Cultural velocity is the moat that's hardest to replicate with capital alone. Zyn spread through conservative political circles, tech-adjacent offices, and social media in ways no advertising budget can manufacture. The Wall Street Journal reported that Zyn use became widespread across the Trump administration, with staff across multiple agencies relying on the pouches through long workdays. That kind of organic embedding creates switching friction that's behaviorally deep and brand-specific.

Big Tobacco Wants Zyn’s Crown

PMI doesn't own nicotine pouches as a category. Altria GroupMO

markets on! pouches and Reynolds American sells VELO in the US. Both companies have national distribution infrastructure, retail relationships built over decades, and the regulatory experience to compete directly. BAT has publicly committed to generating half its revenue from smokeless products by 2035, which signals serious, sustained resource allocation behind its US push.

The competitive risk isn't a sudden reversal of Zyn's market position. The risk is that category growth gets distributed more evenly than current share figures suggest, and the premium PMI carries for leading the smoke-free transition gets compressed as rivals close the gap.

The youth exposure issue is the specific regulatory threat a sharp skeptic would prioritize. Mitch Zeller, a former senior tobacco regulator at the FDA, put it directly: "These products could be a huge help to addicted smokers who would be interested in switching to them. On the risk side, the challenge is that these flavors can be appealing to children. And even if these products are less risky than cigarettes, no kids should be initiating on these products."

Meghan Morean, a research scientist at the Yale School of Medicine, offered a scientific qualifier that applies equally to the regulatory picture: "It's good that we're moving towards a harm reduction approach. But nicotine itself is not completely without risk." Cardiovascular effects and withdrawal potential mean the product category carries a liability profile that regulators could revisit, particularly if youth uptake data worsens.

Geopolitical exposure adds a separate layer of risk specific to PMI's international structure. The company trimmed its full-year 2026 guidance, citing higher transport and energy costs tied to Middle East conflict. For a company generating much of its revenue outside the US, macroeconomic disruptions hit differently than they do for purely domestic consumer brands.

What the Smoke-Free Transition Is Actually Worth

The investment thesis on PMI is a bet on the pace and permanence of its revenue shift. Smoke-free products at 43% of total revenue is already well past the halfway point toward a two-thirds target PMI needs to hit by 2030. The trajectory gives the company credibility on its timeline that more aspirational pivots from competitors don't yet have.

The regulatory environment is also unusually favorable right now. The FDA policy shift, which followed a meeting between President Trump and tobacco executives per The Wall Street Journal, allows more pouch products to reach retail without full scientific authorization. PMI, with existing authorized products and completed filings already in the system, sits structurally ahead of any entrant starting that process today.

The counterargument centers on durability. Zyn's cultural moment is real, but a brand whose rise tracks closely with a specific political and social moment carries some of the concentration risk that comes with trend-dependent products. The more durable moat is the FDA clearance and the manufacturing capacity, not the influencer endorsements or the White House adjacency.

PMI's valuation reflects a company in transition, priced ahead of the outcome it's pursuing. The forward case rewards investors who believe two-thirds smoke-free revenue by 2030 is achievable and that the profitability of that mix outperforms the cigarette business it displaces. Shares rose as much as 3.6% after Q1 2026 results despite pulling back ~19% since the start of the Iran conflict through the prior session's close. The market punished the macro exposure but rewarded the earnings quality.